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SUMMARY Discoid lupus erythematosus (DLE) is the most common form of 
chronic cutaneous lupus erythematosus. It tends to heal with scarring, hair loss, 
and pigmentary changes if treatment is not initiated in the early phase of the 
disease. Classic DLE lesions are initially red-purple macules, papules, or small 
plaques that rapidly acquire a hyperkeratotic appearance. Only a minority of 
patients with DLE progress to develop systemic lupus erythematosus (SLE). A 
small percentage of patients with SLE have concomitant DLE. However, gen-
eralized DLE is more frequently associated with systemic involvement than 
classic DLE. The diagnosis of DLE is usually based on clinical features, although 
in some cases histopathological examination may be required to confirm the 
diagnosis. Standard therapy for cutaneous lupus erythematosus includes 
broad-spectrum sunscreens, topical and intralesional glucocorticoids, and 
antimalarial agents. A 63-year-old man presented with erythematous scaly 
patches that he had on the face for approximately eight months. Although 
the face was the main affected site, lesions were also noted on the scalp, neck, 
chest, shoulder, upper arms, and trunk. Histopathological examination veri-
fied the diagnosis of DLE. Laboratory examination and consultation with other 
departments did not reveal any systemic involvement. Imiquimod cream 5% 
was applied three times a week, every other week. After 24 applications over 
a period of two months, an almost complete recovery was achieved. Topical 
imiquimod may be an alternative treatment for generalized DLE. 
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InTRoDUCTIon
Discoid lupus erythematosus (DLE) is a chronic 
dermatosis characterised by clearly demarcated ery-
thematous patches or plaques that are especially 
likely to occur on sun-exposed areas. DLE is probably 
more likely to occur in individuals who are genetically 
inclined, although definitive genetic risk factors have 
not yet been identified. The condition generally be-
comes evident after exposure to ultraviolet (UV) light, 
but trauma, mental stress, and exposure to cold may 
also act as triggers (1,2). Although the pathophysiolo-
gy of DLE is not well known, it was claimed that a trig-
gering factor such as UV light or stress can activate 
a heat shock protein in keratinocytes. This protein 
might play a key role in T-cell mediated epidermal 
cell cytotoxicity (3,4). Recent publications emphasise 
the role of the toll-like receptors in the pathogenesis 
of DLE (5-7). 
DLE accounts for 55-85% of cases of cutaneous lu-
pus erythematosus (CLE) (8, 9). Lesions may clinically 
appear as verrucous, hypertrophic, or telangiectatic 
lesions. Facial lesions expand and join together, lead-
ing to a butterfly-shaped rash in the malar region. 
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This rash is the characteristic skin lesion associated with 
DLE(1). Over time, hyperpigmentation may develop 
around the discoid lesions. Plaques and a poikilodermic 
appearance also develop as a result of atrophic scar-
ring and telangiectasies (8). Several DLE lesions may be 
found on the head and neck in patients in the localized 
form of the disease. However, disseminated or gener-
alised DLE is associated with lesions that are widely dis-
tributed on the body with or without head and neck 
involvement (10). Hematological and serological ab-
normalities are commonly associated with the dissemi-
nated form of the disease, which is also associated with 
a higher risk a  of systemic involvement and is more dif-
ficult to treat than the localized form (1).
It is necessary to treat DLE in order to improve the 
patient’s appearance, to control existing lesions, to 
make scarring minimal, and to prevent the develop-
ment of more lesions. However, therapy continues to 
be a serious problem for clinicians because the dis-
ease tends to reoccur. 
Standard therapy for CLE includes broad-spec-
trum sunscreens, topical, intralesional and/or sys-
temic glucocorticoids, antimalarial agents such as hy-
droxychloroquine, chloroquine and quinacrine, reti-
noids, and dapsone (11). In this paper we report on 
the successful treatment of a 63-year-old man with 
generalized DLE with topical imiquimod.
CASE REpoRT
A 63-year-old man came to our clinic with general-
ized, erythematous, and clearly demarcated plaques 
on his face, neck, scalp, shoulder, chest, and upper ex-
tremities (Figure 1, 2). The lesions had developed on 
his face about eight months earlier and then spread 
accross the entire face and to other areas of his body. 
The patient’s personal and family history was unre-
markable. He denied any personal or family history 
of photosensitivity or any connective-tissue disease. 
The systemic physical examination did not reveal any 
pathological findings. 
Histopathological examination of the lesions 
revealed superficial hyperkeratosis with follicular 
plugging covered by an atrophic epidermis, epider-
mal dyskeratotic cells, vacuolar degeneration of the 
basal layer, periadnexal, interstitial and perivascular 
lymphocytic infiltrates, erythrocyte extravasation, 
edema, and vasodilation in the dermis (Figure 3). A 
diagnosis of generalized DLE was made based on 
the clinical, histopathological, serological and im-
munological findings. Laboratory evaluations were in 
the normal range, including a red blood cell count, 
hemoglobin, hematocrit, erythrocyte sedimentation 
rate, serum biochemistry, and urinalysis. Serological 
and immunological parameters failed to uncover any 
pathology. Anti-double-stranded DNA (dsDNA), SS-A, 
SS-B, Smith and ribonucleoprotein antibodies were 
negative. Immunoglobulins (IgG, IgM, IgA) and com-
plements (C3, C4) were within normal limits. A rapid 
plasma reagin test was non-reactive. Pulmonary X-ray 
and abdominopelvic ultrasonography were normal, 
and no systemic involvement was detected. 
The patient did not consent to systemic adminis-
tration of corticosteroids, and his lesions continued 
Figure 1, 2. Erythematous and clearly demarcated plaques on the face, neck and chest
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to be active after one month of topical steroid ther-
apy. Therefore, we initiated treatment with topical 
imiquimod cream 5%, applied three times a week. 
After two weeks of treatment, erythema and crusting 
developed on the lesions. Treatment was interrupted 
for a few days to allow the crusts to heal, and then im-
iquimod cream was applied for a total of eight weeks. 
With the topical imiquimod therapy, the lesions grad-
ually regressed and healed significantly after two 
months. No adverse effects were seen except for lo-
cal inflammatory reactions and a thin crust formation 
at the site of treatment and the adjacent skin. At the 
end of the treatment, the patient had been clinically 
cured of the disease (Figure 4 and 5). By the time of 
his one year follow-up, there had been no recurrence 
and no new lesions had developed.
DISCUSSIon 
DLE treatment aims to control the number of le-
sions, to minimize scarring, and to prevent the oc-
currence of new lesions. Standard medical therapy 
consists of topical or intralesional corticosteroids 
and antimalarial medications, and broad-spectrum 
sunscreens are recommended for all patients. Anti-
malarial agents such as hydroxychloroquine, chloro-
quine, and quinacrine are indicated when topical or 
intralesional therapy fails to control the skin disease 
(2,4) Alternative therapeutic options include topical 
or systemic retinoids, thalidomide, dapsone, clofazi-
mine, auranofin, gold, sulfasalazine, and immunosup-
pressive agents such as methotrexate and mycophe-
nolate mofetil (12). Cryotherapy and laser therapy 
Figure 3. Superficial hyperkeratosis with follicular 
plugging covered by an atrophic epidermis, epider-
mal dyskeratotic cells, vacuolar degeneration of the 
basal layer, superficial and deep perivascular lympho-
cytic infiltration [hematoxylin and eosin stain (H&E); 
original magnification X100]
Figure 4, 5. Appearance of the lesions on the face af-
ter imiquimod therapy (after12 weeks)
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have been reported as therapeutic alternatives for 
DLE in literature (13,14).  
Topical calcineurin inhibitors have recently been 
successfully used in patients with SLE with skin le-
sions, but these inhibitors have a limited ability to 
penetrate discoid lesions. Gerdsen et al. reported that 
they successfully treated a case with DLE of the scalp 
through the use of imiquimod cream 5% (15). In 2006, 
successful treatment with imiquimod therapy was re-
ported by Gul et al. in patients with generalized DLE 
where lesions involved the face in particular (16).
Emertcan et al. reported on the treatment of a case 
where microinvasive squamous cell carcinoma (SCC) 
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developed on the DLE lesions on the lip and around 
the ears. The patient was treated for five days a week 
with topical imiquimod 5% and achieved complete 
healing within two weeks (17). 
We found only one case of generalized DLE in the 
literature that was successfully treated with topical 
imiquimod. In 2006, Gul et al. reported on therapy that 
included topical imiquimod once a day, three times a 
week, for a patient with DLE lesions that were located 
mainly on the face. The lesions totally cleared after 20 
applications and, except for local irritation, no serious 
side effects were noted (16). Our case represents the 
second time that topical imiquimod cream was used 
successfully in the treatment of generalized DLE.
Imiquimod modifies the immune response and has 
antitumor, antiviral, and immunoregulatory properties. 
Imiquimod acts on both innate and adaptive immune 
responses. It stimulates production of pro-inflamma-
tory cytokines such as IL-2, IL-12, IL-18, IFN-α, and IFN-
γ by activating the toll-like receptor 7 and the nuclear 
factor kappa B signaling pathway (18). Imiquimod has 
also been shown to increase T-helper type 1 (Th1) im-
mune responses and to decrease T-helper type 2 (Th2) 
immune responses. In addition, it activates antigen 
presentation to T lymphocytes by Langerhans cells and 
induces apoptosis of the tumor cells through caspase 
activation. The Food and Drug Administration has ap-
proved imiquimod for the treatment of genital warts, 
actinic keratoses of the head and neck, and superficial 
basal cell carcinoma. DLE has been reported as one of 
the off-label indications for imiquimod (19).
Topical imiquimod therapy may cause several side 
effects, ranging from mild local reactions to serious 
systemic side effects. Most common local reactions 
are erythema, scabbing, erosion, induration, edema, 
and ulceration. Less common systemic side effects 
are flu-like symptoms, headache, back pain, muscle 
aches, tiredness, fatigue, swollen lymph nodes, nau-
sea, diarrhea, infections, postural hypotension, and 
changes in skin color (20).  
Burnett et al. reported on the development of au-
toimmune retinitis with subacute cutaneous lupus 
erythematosus (SCLE) in a 56-year-old female pa-
tient who was treated with 5% imiquimod for actinic 
keratosis. Authors suggested IFN-alpha, which plays 
an important role in the pathogenesis of SCLE, may 
be associated with this condition (21). Development 
of lupus erythematosus-like reactions in the treated 
region was reported by Chan et al. in two different 
patients (20). These cases indicate diverse imiquimod 
reaction patterns.
How imiquimod acts in treating DLE is uncertain. 
Its effect may be associated with the increased levels 
of IFN-alfa. In the literature there are several reports 
of DLE and SCLE cases that were treated with IFN alfa 
2a (22). Similarly, Martinez et al. reported on the treat-
ment of two DLE patients with intralesional IFN-alpha 
2b (23). The authors suggested that IFN-alfa anti-in-
flammatory effects are based on the down-regulation 
of lymphokin production. Mori et al. also reported 
that expression of functionally meaningful molecules 
from Langerhans cells suggests the impairment of 
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Table 1. Cases of DLE treated successfully with imiquimod in the literature
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their immunologic efficiency. The effect of imiqui-
mod on DLE may be associated with its modifying 
effect on Langerhans cells. However, extended phar-
macodynamic studies are needed in order to explain 
imiquimod’s effects on DLE. 
ConCLUSIon 
There are several cases of DLE treated successfully 
with imiquimod to be found in the literature. Imiqui-
mod may be a therapeutic option for refractory cases 
in which standard therapy modalities are ineffective 
or contrindicated. More controlled clinical trials are 
needed to draw any further conclusions.
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